Welcome to our dedicated page for Rocket One SEC filings (Ticker: RKTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Rocket One's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Rocket One's regulatory disclosures and financial reporting.
Rocket One Inc. (RKTO), formerly Hoth Therapeutics, reports no revenue and a larger loss while shifting its focus from purely biopharmaceuticals to AI semiconductor infrastructure. For the six months ended June 30, 2026, net loss was $6,527,116 versus $5,675,312 a year earlier, driven by higher research and development and general and administrative expenses.
Total assets increased to $9,584,874 from $7,603,444 at year-end 2025, including cash and cash equivalents of $7,891,911. Operating cash outflow was $6,019,382 for the first half of 2026. The company has an accumulated deficit of $79,406,459, but management states current cash is sufficient to fund operations for at least 12 months from issuance.
Rocket One funded operations through equity: it sold 4,193,178 shares via an at-the-market program for net proceeds of $5,847,063 and completed an April 2026 registered direct and concurrent private placement raising net $1,611,880 and issuing new warrants. Shares outstanding rose to 23,184,634 at June 30, 2026. The company exited its prior crypto asset positions and began reporting two segments: a legacy biopharmaceutical segment and a new AI Infrastructure and Technologies segment.
Rocket One Inc. reported that on August 6, 2026 it received a Nasdaq deficiency notice because its common stock no longer meets Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for 30 consecutive business days. The notice does not immediately affect trading and the shares continue to trade on The Nasdaq Capital Market under the symbol RKTO.
The company has 180 calendar days, until February 2, 2027, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days, with the possibility of an additional 180-day period subject to conditions. Rocket One states it will monitor its share price and may consider options such as a reverse stock split. Separately, the company announced acceptance into the Seagate Partner Program, gaining access to enterprise data storage resources as it develops AI infrastructure, space, and defense computing technologies.
Rocket One Inc. increased the maximum aggregate offering price of its common stock issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC to include up to an additional $5,257,000 in shares. This increase is separate from approximately $13,557,905 of shares of common stock that were sold to date pursuant to the same Sales Agreement; this is a baseline figure, not the amount being offered.
The company also filed a Current Prospectus Supplement and obtained a legal opinion from Sheppard Mullin Richter & Hampton LLP regarding the legality of the $5,257,000 in shares of common stock covered by the supplement.
Rocket One Inc. is amending its existing shelf registration to increase the capacity for primary sales of common stock under its Sales Agreement with H.C. Wainwright & Co. It is now offering up to an additional $5,257,000 of common stock, from time to time.
Previously, the company sold 9,825,684 shares for gross proceeds of approximately $13.56 million under this agreement. As of June 2, 2026, public float was about $54,043,646, with 24,897,581 shares outstanding and 24,343,985 held by non-affiliates at $2.22 per share, guiding the one-third public float limit under General Instruction I.B.6 of Form S-3. The last reported sale price on July 27, 2026 was $0.7717 per share.
Rocket One Inc. is expanding its AI infrastructure strategy through a strategic collaboration with Placeve Inc., which includes an initial investment and joint evaluation of Placeve’s AI processor architecture, software platform and machine‑learning technologies for defense, space and intelligent edge computing. Placeve’s photonic‑electronic AI processor technology is being evaluated through NASA’s Materials International Space Station Experiment (MISSE) program aboard the International Space Station.
Rocket One also prepared investor presentation materials outlining three core platforms: a nanomagnetic matrix multiplier compute‑in‑memory accelerator targeting ~5 ns, ~500 aJ multiply‑and‑accumulate operations; skyrmion‑mediated spintronic memory switching in ~1 ns at 100–1,000× lower energy than commercial STT‑MRAM with intrinsic radiation tolerance; and the Swarm Stage AI autonomous swarm defense and training platform with over 2,500 field‑tested formations. Together with its existing biotechnology programs held in a subsidiary, these initiatives support an integrated AI and space‑oriented infrastructure strategy.
Rocket One Inc. has regained full compliance with Nasdaq’s minimum bid price requirement for its RKTO common stock. Nasdaq notified the company that, for the ten consecutive business days from June 9 through June 23, 2026, Rocket One’s closing bid price stayed at or above $1.00 per share, satisfying Listing Rule 5550(a)(2). As a result, the company’s continued listing on The Nasdaq Capital Market is no longer at risk from this issue. Management links this milestone to its ongoing strategic shift from biotechnology to advanced AI computing, defense infrastructure, and space-enabling technologies.
Rocket One Inc., formerly Hoth Therapeutics, has amended its Nevada charter to change its corporate name to Rocket One Inc. effective May 26, 2026. The company’s common stock will begin trading on The Nasdaq Capital Market under the new ticker “RKTO” on May 28, 2026, replacing “HOTH.”
The company is repositioning around the “orbital economy,” focusing on next-generation nanomagnetic AI chip technology designed for ultra-low-power, radiation-tolerant computing in space and defense applications. Its legacy biotechnology programs will continue under a wholly owned subsidiary, now named Rocket One.0 Inc. Shareholder rights and the CUSIP for the common stock remain unchanged.